Currently, Domvanalimab, an investigational inhibitor, is being evaluated in clinical trials in combination Zimberelimab (anti-PD-1) in recurrent glioblastoma (NCT04656535, Table 1). The gene discussed is PDCD1; the disease is glioblastoma.